Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents ... Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium.
News
- Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical ...
- SABCS Data Solidifies Enhertu as Preferred Second-, Third-Line HER2-Positive Breast ...
SAN ANTONIO – Two Phase II trials of Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) confirmed the drug's benefit as a second- ...
- DFS Improved With AIs vs Tamoxifen in HR+, HER2- Early Breast Cancer
... presented in a poster at the San Antonio Breast Cancer Symposium 2022. ... Disclosures: Some study authors declared affiliations with biotech, ...
- Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines ... - BioSpace
DAN-222 Phase 1 dose-escalation data at San Antonio Breast Cancer Symposium ... Dantari, Inc. is a clinical-stage biotechnology company developing ...
- Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset ...
... One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS) ...